Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan

OBJECTIVES: A number of publications have demonstrated the cost-effectiveness of sofosbuvir plus ribavirin (SOF+RBV) compared with the former standard therapy with interferon (IFN)-containing regimens. Unlike these cost-effective analyses, where efficacy parameters were obtained from registration tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Igarashi, Ataru, Furusyo, Norihiro, Ogawa, Eiichi, Nomura, Hideyuki, Dohmen, Kazufumi, Higashi, Nobuhiko, Takahashi, Kazuhiro, Kawano, Akira, Azuma, Koichi, Satoh, Takeaki, Nakamuta, Makoto, Koyanagi, Toshimasa, Kato, Masaki, Shimoda, Shinji, Kajiwara, Eiji, Hayashi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588956/
https://www.ncbi.nlm.nih.gov/pubmed/31221866
http://dx.doi.org/10.1136/bmjopen-2018-023405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588956/
https://www.ncbi.nlm.nih.gov/pubmed/31221866
http://dx.doi.org/10.1136/bmjopen-2018-023405

Ejemplares similares